Why Farbe Firma is the Top Manufacturer of Levosulpiride Injection
- Maulik Sudani
- 1 day ago
- 8 min read
Last Updated: June 22, 2026
TL;DR: Levosulpiride Injection — a sterile, clear, colourless aqueous solution of levosulpiride, the pharmacologically active levo-enantiomer of the substituted-benzamide sulpiride, which works through a dual mechanism as a selective dopamine D2 receptor antagonist and a serotonin 5-HT4 receptor agonist to give it combined prokinetic, antiemetic and antipsychotic activity, supplied commonly as a 25 mg/2 mL solution in an ampoule given by intramuscular injection — is a widely used hospital medicine for dyspepsia, nausea, vomiting, diabetic gastroparesis and other gastrointestinal motility disorders when oral therapy is not feasible, and for selected psychiatric indications. Because the active is a single enantiomer and the dose is delivered parenterally to patients who often cannot take medicines by mouth, each ampoule must deliver an exact, sterile, particulate-free dose at the labelled strength, with the stability-indicating assay, the enantiomeric (chiral) purity, the related-substance profile, solution pH, fill volume, low particulate and endotoxin, a validated sterilisation route, light-protective packaging and verified container-closure integrity all mattering to safety and shelf life. Farbe Firma Pvt Ltd manufactures WHO-GMP certified Levosulpiride Injection at our Gujarat, India facility and supplies it to gastroenterology, internal-medicine, psychiatry and hospital-pharmacy services, tenders, distributors and brand owners across 30+ countries.
Key Takeaways
Drug class: Substituted-benzamide prokinetic and antipsychotic — levosulpiride, the active levo-enantiomer of sulpiride, acts as a selective dopamine D2 receptor antagonist and 5-HT4 receptor agonist, and Levosulpiride Injection (25 mg/2 mL, intramuscular) delivers fast, reliable relief in dyspepsia, nausea, vomiting and diabetic gastroparesis when oral dosing is not feasible, where an exact, reproducible parenteral dose is essential.
Certified manufacturing: WHO-GMP certified plant, ISO Class 5 aseptic core, validated water-for-injection loops, dedicated light-protected compounding and ampoule filling lines, control of the stability-indicating assay, the enantiomeric (chiral) purity, the related-substance profile, solution pH, fill volume, particulate and endotoxin, with container-closure integrity verification on every batch.
CTD-ACTD dossier support: Full eCTD and ACTD modules, ICH Q1A long-term and accelerated stability data, ICH Q1B photostability data, chiral and stability-indicating method-validation data, sterilisation and container-closure data, drug master files and CEP-style documentation for registrations including ministry-of-health, hospital-formulary and institutional tenders.
End-to-end CDMO services: Sterile-solution ampoule contract manufacturing, third-party manufacturing, private-label artwork, multilingual leaflets, tamper-evident tender-ready packaging and import/export coordination for buyers in Africa, LATAM, CIS, GCC, MENA and Southeast Asia.
Introduction: Why Levosulpiride Injection Demands a Premium Manufacturer
Levosulpiride Injection holds a practical, everyday place in gastroenterology wards, internal-medicine units, post-operative recovery, oncology supportive care and psychiatry across many markets. It is the substituted benzamide clinicians reach for when a patient cannot keep medicines down — to settle nausea and vomiting, to restore stomach and gallbladder emptying in functional dyspepsia and diabetic gastroparesis, and to control the symptoms of reflux and dysmotility when the oral route has failed. What makes levosulpiride distinctive is its dual pharmacology: it is the active levo-enantiomer of sulpiride and works both as a selective dopamine D2 receptor antagonist and as a serotonin 5-HT4 receptor agonist, a combination that delivers prokinetic, antiemetic and, at the receptor level, antipsychotic activity. Because the injection is given to patients who are already unwell and often unable to take anything by mouth, the dose delivered from each ampoule must be exact, sterile, particulate-free and reliably the same from unit to unit, since the prescriber depends on a precise, ready, reproducible parenteral dose.
That clinical reality places real demands on the manufacturer. Levosulpiride Injection is a low-strength aqueous solution — typically 25 mg in a 2 mL ampoule — so the assay must be exact and the fill volume accurate so each unit delivers the labelled content. Critically, the active is a single enantiomer: only the levo form carries the desired activity, so the manufacturer must control the enantiomeric (chiral) purity by a validated chiral method and keep the unwanted enantiomer and other related substances within tight limits, because chiral integrity is part of what makes "levosulpiride" different from racemic sulpiride. The molecule is also a benzamide that is sensitive to light, so the solution must be compounded at a controlled pH, protected from light during processing and packaged to defend it across shelf life under a validated ICH Q1B photostability programme. The solution must be free of visible and sub-visible particulates and low in endotoxin, the route and the dopamine-antagonist class warnings — extrapyramidal symptoms, raised prolactin and, with prolonged use, tardive dyskinesia — clearly carried on the label, and the right sterilisation route — terminal moist-heat where the formulation and container qualify, otherwise full aseptic processing — selected and validated. Choosing a Levosulpiride Injection manufacturer that treats the stability-indicating assay, chiral purity, related-substance and pH control, photostability, fill-volume accuracy, particulate and endotoxin control and container-closure integrity as core engineering disciplines is what protects the patient at the point of care.
What Sets a World-Class Levosulpiride Injection Manufacturer Apart
A world-class manufacturer of Levosulpiride Injection invests in three areas that weaker suppliers underfund: a precise, stability-indicating assay of levosulpiride with enantiomeric (chiral) purity and related-substance control by validated HPLC — accurate at the low 25 mg/2 mL strength — that a single-enantiomer benzamide demands, a robust, validated, light-protected sterilisation and fill process that protects sterility, clarity, pH and chiral integrity in a photosensitive solution, and tender-ready dossier support for a high-volume gastroenterology and hospital-formulary product procured through pharmacy and ministry-of-health channels. It starts with the active — pharmacopoeial-grade levosulpiride sourced from qualified, audited API makers, with full assay, chiral-purity, related-substance and impurity profiling and certificates of analysis verified by the receiving laboratory before the material enters production.
Compounding and filling then have to defend the assay, the clarity, the pH and the chiral purity of the solution. The bulk solution is compounded in water-for-injection at the controlled pH that keeps levosulpiride soluble and stable, then sterile-filtered through 0.22 µm membrane and filled into ampoules under ISO Class 5 conditions with the workflow shielded from light, with the validated sterilisation route — terminal moist-heat where the formulation and container qualify, otherwise full aseptic processing — locked in the master batch record. Filled units are 100 % inspected for fill, seal, clarity and particulate defects; in-process and release testing confirm the assay of levosulpiride by validated HPLC, the enantiomeric (chiral) purity, the related-substance profile, solution pH, deliverable (fill) volume, visible and sub-visible particulate matter, and that endotoxin is held well within limits so the solution is safe for intramuscular administration. Because levosulpiride is a single-enantiomer, light-sensitive benzamide, assay accuracy, chiral-purity control, photostability, light-protective packaging and container-closure integrity are validated together so the assay, chiral purity and clarity stay within specification across shelf life.
Quality Systems Behind Every Levosulpiride Injection
Every Farbe Firma Levosulpiride Injection batch is released only after a full stack of quality checks: stability-indicating HPLC assay of levosulpiride against pharmacopoeial reference standards, enantiomeric (chiral) purity by validated chiral HPLC, control of related substances by HPLC, solution pH, clarity and colour of the solution, deliverable (fill) volume, visible and sub-visible particulate matter, bacterial endotoxin by LAL, sterility by membrane filtration, and container-closure integrity for the ampoule format. Certificates of analysis are issued with full traceability back to each API lot, the primary-packaging lot and the qualified person responsible for release.
Around those release tests sits a deeper quality architecture: validated water-for-injection generation and looped distribution, qualified HVAC with continuous environmental monitoring, validated sterilisation and depyrogenation equipment, validated light-protected filling lines with 100 % inspection, and an electronic batch record system tied into our deviation, change-control and CAPA workflows. Because levosulpiride injection is a single-enantiomer, light-sensitive benzamide given parenterally and the assay, chiral purity, related-substance profile, pH, particulate and endotoxin burden drive both efficacy and safety, we treat the stability-indicating assay, the enantiomeric purity, the related-substance profile, the solution pH and the deliverable volume as critical quality attributes and trend them across batches, not merely as one-off release tests. Stability is tracked under both long-term (25 °C / 60 % RH) and accelerated (40 °C / 75 % RH) ICH Q1A conditions, with a full ICH Q1B photostability challenge, so the assay, chiral purity, clarity and pH stay within specification across the labelled shelf life.
Looking for a sterile injectable manufacturing partner? Submit a Quick Inquiry
Why Farbe Firma is the Trusted Levosulpiride Injection manufacturer for Global Buyers
Farbe Firma Pvt Ltd manufactures more than 100 sterile injectables, including a broad gastroenterology, internal-medicine and supportive-care small-volume parenteral portfolio. For Levosulpiride Injection specifically, we supply the 25 mg/2 mL solution in the ampoule presentation under WHO-GMP conditions, with country-specific strengths, fill configurations, light-protective tamper-evident packs and pack counts available under contract manufacturing agreements. Every batch is released to WHO-GMP standards, with the underlying CTD or ACTD dossier — including the stability-indicating-assay, chiral-purity, related-substance, pH, sterilisation and container-closure data package — ready to hand for registration and tender qualification.
Our CDMO services scale cleanly from single-hospital supply to full national tender procurement. We prepare complete eCTD and ACTD modules, drug master files, ICH Q1A stability and ICH Q1B photostability packages, chiral and stability-indicating method-validation data, sterilisation and container-closure reports, translated package inserts and artwork — including intramuscular-route, protect-from-light handling and dopamine-antagonist class warnings for extrapyramidal symptoms, raised prolactin and tardive dyskinesia — for Spanish, French, Portuguese, Russian and Arabic markets, and coordinate shipping and logistics to the destination market. When a buyer needs Levosulpiride Injection at tender scale our regulatory, manufacturing and logistics teams move as one: dossier, validation reports, artwork, line slot and shipment plan delivered as a single coordinated package.
Buyers stay with Farbe Firma because of audit-readiness and communication. Customer auditors are welcomed onto the plant floor and into the compounding and filling suites; our quality unit answers technical queries with primary data, not slogans; and our reviewer team — practising pharmacists and R&D scientists — can talk through API sourcing, stability-indicating and chiral assay development, related-substance control, pH formulation design, light-protective process and packaging engineering, the choice between terminal sterilisation and aseptic filling, fill-volume and deliverable-dose accuracy, particulate and endotoxin control, container-closure integrity and shelf-life choices in real detail. For a single-enantiomer benzamide where assay accuracy, chiral purity and dose precision directly govern both efficacy and safety, that openness is exactly what global buyers tell us they value most.
Explore Farbe Firma: Products | Global Reach | About Us
Frequently Asked Questions (FAQ)
Is Farbe Firma a WHO-GMP certified Levosulpiride Injection manufacturer?
Yes. Farbe Firma Pvt Ltd holds WHO-GMP certification and manufactures Levosulpiride Injection at a Gujarat, India facility with ISO Class 5 aseptic processing, validated water-for-injection systems, dedicated light-protected compounding and ampoule filling lines, validated sterilisation, 100 % inspection and continuous environmental monitoring.
Which strengths and pack sizes of Levosulpiride Injection do you supply?
Our standard presentation is the 25 mg/2 mL solution of levosulpiride in an ampoule, given by intramuscular injection. Custom strengths, fill configurations, ampoule formats, light-protective tamper-evident counts per pack and country-specific artwork are available under contract manufacturing agreements.
What is Levosulpiride Injection mainly used for?
Levosulpiride Injection is used for dyspepsia, nausea, vomiting, diabetic gastroparesis and other gastrointestinal motility disorders when oral therapy is not feasible, and for selected psychiatric indications. It is the active levo-enantiomer of the benzamide sulpiride and acts as a dopamine D2 receptor antagonist and 5-HT4 receptor agonist; Farbe Firma verifies the assay, chiral purity, related-substance profile, pH, deliverable volume, particulate matter and endotoxin at release so each ampoule delivers a precise, reproducible dose.
Can Farbe Firma support country-specific registrations for Levosulpiride Injection?
Yes. We provide full CTD and ACTD dossier modules, drug master files, ICH Q1A stability and ICH Q1B photostability packages, chiral and stability-indicating method-validation data, sterilisation and container-closure reports, and translated package inserts and artwork for Spanish, French, Portuguese, Russian and Arabic markets. We support registrations and tender qualification in 30+ countries across Africa, LATAM, CIS, GCC, MENA and Southeast Asia.
What is the minimum order quantity for Levosulpiride Injection contract manufacturing?
MOQs vary by strength, ampoule size, sterilisation route, light-protective packaging, label complexity and dossier requirements. For our gastroenterology and supportive-care small-volume parenteral presentations we accommodate hospital-scale and full national-tender-scale orders. Contact director@farbefirma.org for a specific quotation.
Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert)
Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA
Request a Quote | View Products | FAQ | Blog
Comments